ImmuPharma plc (LSE:IMM) advanced 5.31% on 1 October 2026, placing the stock among the stronger movers in its part of the UK market. The gain has increased investor attention at a time when small- and mid-cap shares are reacting sharply to fresh corporate milestones, …
Arecor Therapeutics PLC (LSE:AREC), the Cambridge-based clinical-stage biotech developing therapeutics for diabetes, obesity and cardiometabolic diseases, was among London's notable decliners on 30 September 2026. The shares dropped 18.08% after the company announced and completed an accelerated bookbuild.
Creo Medical Group Plc (LSE:CREO), the developer of advanced energy devices for minimally invasive surgical endoscopy, published its interim results on 30 September 2026. Despite headline growth and cost savings, the shares fell 12.42% as investors focused on the shape of the year and …
Since the interim results on 22 September, the stock has stabilised around the 500p level. Director buying and reassurance that guidance remains intact have helped rebuild confidence.
Shield Therapeutics plc commercialises ferric maltol, marketed as Accrufer in the US and Feraccru elsewhere, an oral treatment for iron deficiency. The US market is its key growth driver. Prescription progress offers a plausible explanation for renewed optimism.
On the evening of 30 September 2026, Verici Dx said it intends to undertake a proposed fundraising with institutional and other investors. SingerCapital Marketsand Oberon Investments are acting as joint bookrunners and brokers. The company said trading in its ordinary shares on AIM would …
Oxford Nanopore Technologies plc develops technology for analysing DNA and RNA in real time. Its platforms serve scientific laboratories, pharmaceutical developers and emerging clinical applications. Improving financial performance and recent healthcare developments provide a plausible explanation for renewed investor optimism. Broader interest in precision …
Oxford Biomedica PLC — LSE:OXB closed 4.17% higher on30 September 2026, with the shares at 525.00p after a gain of 21.00p on the day.
Oxford Nanopore Technologies PLC — LSE:ONT closed 7.42% higher on30 September 2026, with the shares at 214.20p after a gain of 14.80p on the day.
•AOTI has reported strong first-half underlyingRevenuegrowth and continues to focus on expanding reimbursement for its TWO2 topical oxygen therapy. The company has highlighted a proposed USMedicarecoverage determination for topical oxygen therapy in diabetic foot ulcers, which could materially expand its addressable market once finalised.